Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HealthCare Global Enterprises Ltd. ( (IN:HCG) ) just unveiled an announcement.
HealthCare Global Enterprises Ltd. reported its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025, showing sustained growth in revenue and profitability. Consolidated revenue from operations rose 13% year-on-year in Q3 FY26 to ₹6,331 million and 16% for the nine-month period to ₹18,931 million, while adjusted EBITDA increased 20% year-on-year in both the quarter and nine months, with margins improving to 17.5% in Q3 and 18.3% for the nine months, driven by operating leverage and stable performance across regional clusters. Management highlighted that the research-led, technology-driven oncology model and focus on high-quality cancer care across medical, radiation and surgical modalities underpin the scalability of the business and support its ongoing expansion across India, positioning HCG at the forefront of specialized oncology care and reinforcing resilient demand even in a seasonally softer quarter.
More about HealthCare Global Enterprises Ltd.
HealthCare Global Enterprises Ltd. (HCG) is India’s largest dedicated cancer hospital network, operating a nationwide, single-specialty oncology platform under the HCG brand. The company focuses on advanced cancer diagnostics, genomics and multi-omics, organ-specific pathology, tumour-board-led treatment decisions, and emerging therapies such as CAR-T, serving patients across both metropolitan and non-metro markets in India and select international locations like Kenya.
Average Trading Volume: 20,033
Technical Sentiment Signal: Hold
Current Market Cap: 85.82B INR
For a thorough assessment of HCG stock, go to TipRanks’ Stock Analysis page.